Effect of hybrid complement regulatory proteins on xenogeneic cells

被引:11
作者
Fukuta, D
Miyagawa, S
Kubo, T
Matsunami, K
Shirasu, A
Hattori, H
Shirakura, R
机构
[1] Osaka Univ, Grad Sch Med, Div Organ Transplantat, Dept Regenerat Med, Suita, Osaka 5650871, Japan
[2] Nipro Corp, Res & Dev Lab, Shiga, Japan
[3] Anim Engn Res Inst, Ibaraki, Japan
关键词
complement regulatory protein; xenogeneic cell; cofactor ability; C4; deposition; DAF; MCP; C1-INH; c4bp; CR1;
D O I
10.1016/S0006-291X(03)00988-4
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
To suppress C3 fragment deposition in the classical pathway complement activation on xenogeneic membranes, decay accelerating factor (DAF) was the most effective molecule among the complement regulatory proteins (CRPs) used in the present study. C3 fragment deposition was closely related to subsequent xenogeneic cell lysis. However, other molecules were also very effective in different ways and include phosphatidylinositol (PI)-anchored short consensus repeat (SCR) 2-4 of membrane cofactor protein (MCP-PI), PI-anchored C1 esterase inhibitor (C1-INH-PI), and PI-anchored SCR8-11 of complement receptor type I (CRI-PI). On the other hand, regarding a strategy for downregulating C4 fragment deposition, the use of only C1-INH-PI and PI-anchored SCR1-3 of the C4b-binding protein (C4bp-PI) was found to be effective. (C) 2003 Elsevier Science (USA). All rights reserved.
引用
收藏
页码:476 / 482
页数:7
相关论文
共 25 条
[1]   Role of membrane cofactor protein (CD46) in regulation of C4b and C3b deposited on cells [J].
Barilla-LaBarca, ML ;
Liszewski, MK ;
Lambris, JD ;
Hourcade, D ;
Atkinson, JP .
JOURNAL OF IMMUNOLOGY, 2002, 168 (12) :6298-6304
[2]   COXSACKIEVIRUS B3 ADAPTED TO GROWTH IN RD CELLS BINDS TO DECAY-ACCELERATING FACTOR (CD55) [J].
BERGELSON, JM ;
MOHANTY, JG ;
CROWELL, RL ;
JOHN, NFS ;
LUBLIN, DM ;
FINBERG, RW .
JOURNAL OF VIROLOGY, 1995, 69 (03) :1903-1906
[3]  
COYNE KE, 1992, J IMMUNOL, V149, P2906
[4]   Mapping of the sites responsible for factor I-cofactor activity for cleavage of C3b and C4b on human C4b-binding protein (C4bp) by deletion mutagenesis [J].
Fukui, A ;
Yuasa-Nakagawa, T ;
Murakami, Y ;
Funami, K ;
Kishi, N ;
Matsuda, T ;
Fujita, T ;
Seya, T ;
Nagasawa, S .
JOURNAL OF BIOCHEMISTRY, 2002, 132 (05) :719-728
[5]   Effect of various forms of the C1 esterase inhibitor (C1-INH) and DAF on complement mediated xenogeneic cell lysis [J].
Fukuta, D ;
Miyagawa, S ;
Yamada, M ;
Matsunami, K ;
Kurihara, T ;
Shirasu, A ;
Hattori, H ;
Shirakura, R .
XENOTRANSPLANTATION, 2003, 10 (02) :132-141
[6]   DIVERSITY OF SITES FOR MEASLES-VIRUS BINDING AND FOR INACTIVATION OF COMPLEMENT C3B AND C4B ON MEMBRANE COFACTOR PROTEIN CD46 [J].
IWATA, K ;
SEYA, T ;
YANAGI, Y ;
PESANDO, JM ;
JOHNSON, PM ;
OKABE, M ;
UEDA, S ;
ARIGA, H ;
NAGASAWA, S .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1995, 270 (25) :15148-15152
[7]  
KINOSHITA T, 1986, J IMMUNOL, V136, P3390
[8]  
KRYCH M, 1994, J BIOL CHEM, V269, P13273
[9]   Decay accelerating activity of complement receptor type 1 (CD35) - Two active sites are required for dissociating C5 convertases [J].
Krych-Goldberg, M ;
Hauhart, RE ;
Subramanian, VB ;
Yurcisin, BM ;
Crimmins, DL ;
Hourcade, DE ;
Atkinson, JP .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1999, 274 (44) :31160-31168
[10]   Characterization of the active sites in decay-accelerating factor [J].
Kuttner-Kondo, LA ;
Mitchell, L ;
Hourcade, DE ;
Medof, ME .
JOURNAL OF IMMUNOLOGY, 2001, 167 (04) :2164-2171